RayKnowChina Research Map
Shortlist0

JinanShandong University

Qilu Hospital of Shandong University

山东大学齐鲁医院

Listed for 38 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

Official links opened and checked on 2026-11-08.

Getting in touch

Research at Qilu Hospital of Shandong University

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌4 papers led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌31 papers led
  3. Hepatocellular carcinoma肝细胞癌80 papers led1 open trial led
  4. Stomach cancer胃癌80 papers led15 open trials led
  5. Hepatoblastoma肝母细胞瘤0 papers led
  6. Retinoblastoma视网膜母细胞瘤1 paper led
  7. Chordoma脊索瘤0 papers led
  8. Osteosarcoma骨肉瘤16 papers led
  9. Gastrointestinal stromal tumour胃肠道间质瘤0 papers led
  10. Neuroblastoma神经母细胞瘤5 papers led
  11. Ewing sarcoma尤文肉瘤1 paper led
  12. Multiple myeloma多发性骨髓瘤3 papers led1 open trial led
  13. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病2 papers led
  14. Aplastic anaemia再生障碍性贫血3 papers led
  15. Haemophagocytic lymphohistiocytosis噬血细胞性淋巴组织细胞增生症2 papers led
  16. Beta thalassaemiaβ 地中海贫血0 papers led
  17. Haemophilia A血友病 A2 papers led
  18. Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病7 papers led
  19. Myasthenia gravis重症肌无力6 papers led
  20. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎8 papers led
  21. Hepatic echinococcosis肝包虫病1 paper led
  22. Idiopathic pulmonary fibrosis特发性肺纤维化4 papers led
  23. Lymphangioleiomyomatosis肺淋巴管平滑肌瘤病1 paper led
  24. Amyotrophic lateral sclerosis肌萎缩侧索硬化症13 papers led
  25. Spinal muscular atrophy脊髓性肌萎缩症0 papers led
  26. Fabry disease法布雷病1 paper led
  27. Pompe disease庞贝病2 papers led
  28. Duchenne muscular dystrophy杜氏肌营养不良1 paper led
  29. Behçet disease白塞病1 paper led
  30. Alport syndromeAlport 综合征1 paper led
  31. IgA nephropathyIgA 肾病2 papers led
  32. Primary biliary cholangitis原发性胆汁性胆管炎0 papers led
  33. Primary sclerosing cholangitis原发性硬化性胆管炎1 paper led
  34. Congenital diaphragmatic hernia先天性膈疝1 paper led
  35. Hirschsprung disease先天性巨结肠3 papers led
  36. Hereditary angioedema遗传性血管性水肿1 paper led
  37. Familial adenomatous polyposis家族性腺瘤性息肉病1 paper led
  38. Leber hereditary optic neuropathyLeber 遗传性视神经病变3 papers led

Not listed for: Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, IgG4-related disease, Moyamoya disease, Wilson disease, Biliary atresia, Takayasu arteritis, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Inherited epidermolysis bullosa, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 4 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 1120222023: 0020232024: 0020242025: 002025

2 hospitals in Jinan for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRadiotherapy techniqueEBV & screeningRecurrent / metastatic disease
Departments in papersENT / head & neck surgeryRadiation oncologyMedical oncology

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 31 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 1.1%.

Papers led
31
2021–2025
Trials led
5
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 6620212022: 5520222023: 5520232024: 4420242025: 882025

6 hospitals in Jinan for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Adebrelimab Combined With Chemotherapy for the Esophageal Squamous Cell Carcinoma
    Phase
    N/A
    Started
    2024-12
    Registry
    NCT07430579

    Age 18 years to 80 years (registered criteria)

    Led by Second Hospital of Shandong University; 1 listed hospital as study siteJinan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRadiotherapyEarly detection & endoscopyImaging & AI
Departments in papersRadiation oncologyGastroenterology / hepatologyRadiology / nuclear medicine

Over half of these papers are lab or animal studies.

Papers it led31
  1. ARL5B Drives Esophageal Squamous Cell Carcinoma Progression via ROCK1-SREBP1-Mediated Lipid Metabolic Reprogramming.2026Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  2. tRNA-Derived Fragment tRF-22 Promotes Immunosuppression by Inhibiting HnRNPAB Ubiquitination in Esophageal Squamous Cell Carcinoma.2026Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  3. Ivor Lewis minimally invasive oesophagectomy versus McKeown approach: short-term benefits and mid-term equivalence in a randomized trial for oesophageal squamous cell carcinoma.2026Surgical endoscopyRCTFree full text
  4. Value of Computed Tomography Scan for Detecting Lymph Node Metastasis in Early Esophageal Squamous Cell Carcinoma.2025Annals of surgical oncology
  5. High MRPL12 expression drives esophageal cancer proliferation, invasion and migration.2025Bulletin du cancer
  6. The GNL3L-MDM2 Interaction Drives Esophageal Squamous Cell Carcinoma Progression.2025Cancer medicineFree full text
  7. Harnessing NKG2D CAR-T cells with radiotherapy: a novel approach for esophageal squamous cell carcinoma treatment.2025Frontiers in immunologyFree full text
  8. tRNA-derived fragment tRF-24 drives CELF1 phase separation to promote oncogenic splicing in esophageal squamous cell carcinoma.2025Journal of experimental & clinical cancer research : CRFree full text
  9. CICADA: a circRNA effort toward the ghost proteome.2025Nucleic acids researchFree full text
  10. LAMA3 overexpression enhances proliferation, migration and invasion in esophageal squamous cell carcinoma based on bioinformatics and experimental validation.2025Scientific reportsFree full text
  11. Artificial intelligence-aided optical biopsy improves the diagnosis of esophageal squamous neoplasm.2025World journal of gastroenterologyFree full text
  12. T cell-related circRNA pairs to predict prognosis of patients with esophageal squamous cell carcinoma.2024International immunopharmacology
  13. CT-based delta-radiomics nomogram to predict pathological complete response after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma patients.2024Journal of translational medicineFree full text
  14. Genetic and molecular characterization of metabolic pathway-based clusters in esophageal squamous cell carcinoma.2024Scientific reportsFree full text
  15. Risk factors for lymph node metastasis in superficial esophageal squamous cell carcinoma.2024World journal of gastroenterologyFree full text
  16. Unveiling the prognostic significance of SOX5 in esophageal squamous cell carcinoma: a comprehensive bioinformatic and experimental analysis.2023AgingFree full text
  17. A novel diagnostic signature of circulating tsRNAs and miRNAs in esophageal squamous cell carcinoma detected with a microfluidic platform.2023Analytica chimica acta
  18. Development and Validation of Esophageal Squamous Cell Carcinoma Risk Prediction Models Based on an Endoscopic Screening Program.2023JAMA network openFree full text
  19. Optimal concentration of Lugol's solution for detecting early esophageal carcinoma: A randomized controlled trial.2023Journal of gastroenterology and hepatologyRCT
  20. KLF5 promotes esophageal squamous cell cancer through the transcriptional activation of FGFBP1.2023Medical oncology (Northwood, London, England)Free full text
  21. BTN3A1 promotes tumor progression and radiation resistance in esophageal squamous cell carcinoma by regulating ULK1-mediated autophagy.2022Cell death & diseaseFree full text
  22. Construction and Evaluation of a Risk Score Model for Lymph Node Metastasis-Associated Circadian Clock Genes in Esophageal Squamous Carcinoma.2022CellsFree full text
  23. Study of PD-1 Inhibitors in Combination with Chemoradiotherapy/Chemotherapy in Patients with Esophageal Squamous Carcinoma.2022Current oncology (Toronto, Ont.)Free full text
  24. Esophageal wall thickness on CT scans: can it predict the T stage of primary thoracic esophageal squamous cell carcinoma?2022Esophagus : official journal of the Japan Esophageal Society
  25. Comparative Analysis of Mutation Status and Immune Landscape for Squamous Cell Carcinomas at Different Anatomical sites.2022Frontiers in immunologyFree full text
  26. A nomogram for screening esophageal squamous cell carcinoma based on environmental risk factors in a high-incidence area of China: a population-based case-control study.2021BMC cancerFree full text
  27. Syntaphilin downregulation facilitates radioresistance via mediating mitochondria distribution in esophageal squamous cell carcinoma.2021Free radical biology & medicine
  28. Screening of tumor grade-related mRNAs and lncRNAs for Esophagus Squamous Cell Carcinoma.2021Journal of clinical laboratory analysisFree full text
  29. Short-term response might influence the treatment-related benefit of adjuvant chemotherapy after concurrent chemoradiotherapy for esophageal squamous cell carcinoma patients.2021Radiation oncology (London, England)Free full text
  30. Integrated bioinformatics analysis of differentially expressed genes and immune cell infiltration characteristics in Esophageal Squamous cell carcinoma.2021Scientific reportsFree full text
  31. KIF4A enhanced cell proliferation and migration via Hippo signaling and predicted a poor prognosis in esophageal squamous cell carcinoma.2021Thoracic cancerFree full text
All its trials on ClinicalTrials.gov, any status8
  1. Clinical Application of an AI-based Dissection Trajectory Prediction System (ADTPS) in Endoscopic Submucosal DissectionActive, not recruitingNCT07757906Lead sponsorN/AStart 2026-08
  2. Neoadjuvant Immunotherapy to ESCCWithdrawnNCT04625543Lead sponsorPhase 2Start 2020-12
  3. Artificial Intelligence for Early Diagnosis of Esophageal Squamous Cell CarcinomaCompletedNCT03759756Lead (inferred)Start 2018-12
  4. Early Detection of Head and Neck Superficial Squamous Cell Carcinoma in Patients With Esophagus Squamous Cell CarcinomaStatus unknownNCT03700398Lead (inferred)N/AStart 2017-10
  5. Lower Lugol's Solution Concentration on Reducing the Adverse Symptoms of Chromoendoscopy With Iodine StainingCompletedNCT03180944Lead (inferred)Phase 2Start 2017-09
  6. Adebrelimab Combined With Chemotherapy for the Esophageal Squamous Cell CarcinomaRecruitingNCT07430579Study siteN/AStart 2024-12
  7. Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma(ESCC).Status unknownNCT04063683Study sitePhase 2Start 2019-10
  8. A Trial of CMNa Combined With Definitive Concurrent Chemoradiotherapy for Locally Advanced ESCCCompletedNCT02721563Study sitePhase 4Start 2016-02
More papers found outside PubMed (not counted)22
  1. 104P ARL5B drives esophageal squamous cell carcinoma progression via ROCK1-SREBP1-mediated metabolic reprogramming2025ESMO Openarticle
  2. 399P ARL5B drives esophageal squamous cell carcinoma progression via ROCK1-SREBP1-mediated metabolic reprogramming2025Annals of Oncologyarticle
  3. Additional file 1 of tRNA-derived fragment tRF-24 drives CELF1 phase separation to promote oncogenic splicing in esophageal squamous cell carcinoma2025Figsharearticle
  4. Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 plus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): Survival results of a phase II trial.2025Journal of Clinical Oncologyconference-abstract
  5. tRNA-derived fragment tRF-24 drives CELF1 phase separation to promote oncogenic splicing in esophageal squamous cell carcinoma2025Figsharesupplementary-materials
  6. 103P Tislelizumab combined with chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: A multicenter, prospective, single-arm, real-world study2024Immuno-Oncology Technologyarticle
  7. Chemotherapy plus camrelizumab versus chemotherapy alone as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (ESCORT-NEO): A multi-center, randomized phase III trial.2024Journal of Clinical Oncologyconference-abstract
  8. First-line TQB2450 plus anlotinib combined with paclitaxel and cisplatin for advanced esophageal squamous cell carcinoma (ESCC): Update results of a multicenter phase II trial.2024Journal of Clinical Oncologyconference-abstract
  9. 95P A single-arm, multicenter phase II trial evaluating TQB2450 plus anlotinib combined with paclitaxel and cisplatin in first-line treatment of advanced esophageal squamous cell carcinoma (ESCC)2023Immuno-Oncology Technologyarticle
  10. SHR-1701 plus chemotherapy as first-line treatment for unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).2023Journal of Clinical Oncologyconference-abstract
  11. TQB2450 plus anlotinib combined with paclitaxel and cisplatin as first-line treatment of advanced esophageal squamous cell carcinoma (ESCC): Update results of a single-arm, multicenter phase Ⅱ trial.2023Journal of Clinical Oncologyconference-abstract
  12. 1207P Neoadjuvant PD-L1 inhibitor (socazolimab) plus chemotherapy in patients with locally advanced esophageal squamous cell carcinoma (ESCC): A multicenter, randomized, double-blind phase II study2022Annals of Oncologyarticle
  13. 164P TQB2450 plus anlotinib combined with paclitaxel and cisplatin as first-line treatment of advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter phase Ⅱ trial2022Immuno-Oncology Technologyarticle
  14. Additional file 1 of OTUB2 Regulates YAP1/TAZ to Promotes the Progression of Esophageal Squamous Cell Carcinoma2022Figsharedataset
  15. Additional file 6 of Silencing of histone deacetylase 3 suppresses the development of esophageal squamous cell carcinoma through regulation of miR-494-mediated TGIF12022Figsharedataset
  16. Association of Esophageal Squamous Cell Carcinoma With the Interaction Between Poor Oral Health and Single Nucleotide Polymorphisms in Regulating Cell Cycles and Angiogenesis: A Case-Control Study in High-Incidence Chinese2022Cancer Controlarticle
  17. Update results of paclitaxel and cisplatin in combination with anlotinib as first-line regimen for patients with advanced ESCC: A multicenter, single-arm, open-label phase Ⅱ clinical trial.2022Journal of Clinical Oncologyconference-abstract
  18. Effect of Long Term Prediagnostic Aspirin Intake on the Prognosis of Esophageal Squamous Cell Carcinoma Receiving Radical Surgery2021Research Squarepreprint
  19. Larotinib in Patients with Advanced and Previously Treated Esophageal Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Overexpression or Amplification: An Open-Label, Multicenter Phase 1b Study2021Research Squarepreprint
  20. Larotinib in Patients with Advanced and Previously Treated Esophageal Squamous Cell Carcinoma with Epidermal Growth Factor Receptor Overexpression or Amplification: An Open-Label, Multicenter Phase 1b Study2021Research Squarepreprint
  21. Update results of paclitaxel and cisplatin in combination with anlotinib as first-line regimen for advanced esophageal squamous cell carcinoma (ESCC): A multicenter, single-arm, open-label phase Ⅱ clinical trial.2021Journal of Clinical Oncologyconference-abstract
  22. Update results of paclitaxel and cisplatin in combination with anlotinib as first-line regimen for patients with advanced ESCC: A multicenter, single-arm, open-label phase Ⅱ clinical trial.2021Journal of Clinical Oncologyconference-abstract

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 80 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.5%.

Papers led
80
2021–2025
Trials led
4
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 111120212022: 111120222023: 232320232024: 141420242025: 19192025

6 hospitals in Jinan for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative Resection
    Phase
    Phase 2
    Started
    2024-07
    Registry
    NCT06454578

    Age 18 years to Not stated (registered criteria)

    Led by Qilu Hospital of Shandong UniversityJinan

  2. Not yet recruiting
    Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High Risk
    Phase
    N/A
    Started
    2025-06
    Registry
    NCT07010588

    Age 18 years to 75 years (registered criteria)

    Led by Peking University People's Hospital; 8 listed hospitals as study sitesBeijing, Changchun, Chongqing, Harbin, Jinan, Qingdao, Wuhan, Xi'an

  3. Not yet recruiting
    TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07350070

    Age 18 years to 75 years (registered criteria)

    Led by Tongji Hospital; 4 listed hospitals as study sitesFuzhou, Jinan, Nanning, Qingdao, Wuhan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisImmunotherapy & targeted drugsImaging, AI & early detection
Departments in papersSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatologyRadiology / nuclear medicinePathology / laboratory medicine
Papers it led80
  1. Reduced visceral adipose tissue area linked to early recurrence in HCC patients with HBV: a parallel mediation analysis.2026Abdominal radiology (New York)
  2. The landscape of gut microbiota in hepatocarcinogenesis: a comprehensive review of pathogenesis and therapeutic interventions.2026International journal of surgery (London, England)Free full text
  3. Impact of thrombocytopenia and coagulopathy on partial hepatectomy and Hassab's operation in patients with cirrhosis: a multicenter retrospective cohort study.2025Annals of medicineFree full text
  4. Temporal Dynamics of Somatic Mutations in Tumor and Plasma Samples From Hepatocellular Carcinoma Patients Pre- and Post-Radioactive Particle Implantation: A Whole-Exome Sequencing Study.2025Biotechnology and applied biochemistry
  5. Hypoxia-Induced Creatine Uptake Reprograms Metabolism to Antagonize PARP1-Mediated Cell Death and Facilitate Tumor Progression in Hepatocellular Carcinoma.2025Cancer research
  6. Targeting FAM111B attenuates mitophagy and increases the sensitivity to lenvatinib treatment by increasing MFN2 stability in hepatocellular carcinoma.2025Cell death & diseaseFree full text
  7. The Role of the Hexosamine-Sialic Acid Metabolic Pathway Mediated by GFPT1/NANS in c-Myc-Driven Hepatocellular Carcinoma.2025Cellular and molecular gastroenterology and hepatologyFree full text
  8. Hyaluronan-mediated motility receptor regulating the Wnt/β-catenin signaling resulting in hepatocellular carcinoma by inhibiting the phosphorylation activity of GSK-3β.2025European journal of medical researchFree full text
  9. An umbrella review of the association between dietary factors and hepatocellular carcinoma risk.2025Food & function
  10. Multi-parameter MRI-based model for the prediction of early recurrence of hepatitis B-associated hepatocellular carcinoma after microwave ablation.2025Frontiers in cellular and infection microbiologyFree full text
  11. SLC12A7 serves as a prognostic and immunotherapeutic biomarker identified by multi-omics analysis.2025Frontiers in immunologyFree full text
  12. Protective Effects of GalNac-Modified Red Blood Cell-Derived Extracellular Vesicles Against Liver Diseases.2025International journal of nanomedicineFree full text
  13. Systemic therapy plus HAIC versus systemic therapy for hepatocellular carcinoma: a systematic review and meta-analysis.2025International journal of surgery (London, England)Free full text
  14. Hyperspectral Imaging for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma Differentiation.2025Journal of biophotonics
  15. Comparison of tenofovir versus entecavir for preventing hepatocellular carcinoma in chronic hepatitis B patients: an umbrella review and meta-analysis.2025Journal of cancer research and clinical oncologyFree full text
  16. Targeting SAMD1 enhances the effect of anti-PD-1 plus lenvatinib therapy in hepatocellular carcinoma by increasing ferroptosis sensitivity and immune response.2025Metabolism: clinical and experimental
  17. Epigenetic modulation with nanosatellite triggers tumoricidal immunity for hepatocellular carcinoma treatment.2025Nature communicationsFree full text
  18. Targeting ferroptosis: the role of non-coding RNAs in hepatocellular carcinoma progression and therapy.2025Naunyn-Schmiedeberg's archives of pharmacology
  19. MYCBP2-mediated HNF4α ubiquitination reprogrammed lipid metabolism in MASH-associated hepatocellular carcinoma.2025Oncogene
  20. Role of endothelial cell markers in prognosis of hepatocellular carcinoma: Integrating bioinformatics analysis and experimental validation.2025PloS oneFree full text
  21. FLT3 is associated with dendritic cell infiltration, tertiary lymphoid structure construction, and predict response to checkpoint inhibitors immunotherapy in solid cancers.2025Scientific reportsFree full text
  22. Multiparametric MRI manifestations of the spontaneous intratumoral coagulative necrosis in HCC.2024Abdominal radiology (New York)
  23. Research on multi-model imaging machine learning for distinguishing early hepatocellular carcinoma.2024BMC cancerFree full text
  24. Brusatol improves the efficacy of sorafenib in Huh7 cells via ferroptosis resistance dependent Nrf2 signaling pathway.2024Biochemical and biophysical research communications
  25. DAP3 promotes mitochondrial activity and tumour progression in hepatocellular carcinoma by regulating MT-ND5 expression.2024Cell death & diseaseFree full text
  26. Gastrointestinal Bleeding Was Diagnosed as Small Intestinal Metastasis of Hepatocellular Carcinoma by Double-Balloon Enteroscopy.2024Digestive diseases and sciences
  27. The effect of age, sex, and eastern cooperative oncology group performance status on the efficacy and safety of immune checkpoint inhibitors in patients with hepatocellular carcinoma: a systematic review and meta-analysis.2024Expert review of anticancer therapy
  28. Hypomethylation of glycine dehydrogenase promoter in peripheral blood mononuclear cells is a new diagnostic marker of hepatitis B virus-associated hepatocellular carcinoma.2024Hepatobiliary & pancreatic diseases international : HBPD INT
  29. MCM4 potentiates evasion of hepatocellular carcinoma from sorafenib-induced ferroptosis through Nrf2 signaling pathway.2024International immunopharmacology
  30. Role of hepatitis B core-related antigen in predicting the occurrence and recurrence of hepatocellular carcinoma in patients with chronic hepatitis B: A systemic review and meta-analysis.2024Journal of gastroenterology and hepatology
  31. Increased Siglec-9/Siglec-9L interactions on NK cells predict poor HCC prognosis and present a targetable checkpoint for immunotherapy.2024Journal of hepatology
  32. Ficolin-3 induces apoptosis and suppresses malignant property of hepatocellular carcinoma cells via the complement pathway.2024Life sciencesFree full text
  33. Palmitoylation of TIM-3 promotes immune exhaustion and restrains antitumor immunity.2024Science immunology
  34. TLR3 activation enhances antitumor effects of sorafenib in hepatocellular carcinoma by activating NK cell functions through ERK and NF-κB pathways.2024Scientific reportsFree full text
  35. Development of a short-term nutritional risk prediction model for hepatocellular carcinoma patients: a retrospective cohort study.2024Scientific reportsFree full text
  36. Development and External Validation of a Nomogram Including Body Composition Parameters for Predicting Early Recurrence of Hepatocellular Carcinoma After Hepatectomy.2023Academic radiology
  37. LAMP2A, LAMP2B and LAMP2C: similar structures, divergent roles.2023AutophagyFree full text
  38. Comparison of clinicopathologic characteristics among patients with HBV-positive, HCV-positive and Non-B Non-C hepatocellular carcinoma after hepatectomy: a systematic review and meta-analysis.2023BMC gastroenterologyFree full text
  39. Efficacy and safety of immune checkpoint inhibitors for hepatocellular carcinoma patients with macrovascular invasion or extrahepatic spread: a systematic review and meta-analysis of 54 studies with 6187 hepatocellular carcinoma patients.2023Cancer immunology, immunotherapy : CIIFree full text
  40. Diacylglycerol lipase alpha promotes hepatocellular carcinoma progression and induces lenvatinib resistance by enhancing YAP activity.2023Cell death & diseaseFree full text
  41. Transcription factor Zhx2 is a checkpoint that programs macrophage polarization and antitumor response.2023Cell death and differentiationFree full text
  42. Adverse events of immune checkpoint inhibitors in hepatocellular carcinoma: a systemic review and meta-analysis.2023Clinical and experimental medicine
  43. Systemic therapy with or without locoregional therapy for advanced hepatocellular carcinoma: A systematic review and network meta-analysis.2023Critical reviews in oncology/hematology
  44. Impact of particle size of multivesicular liposomes on the embolic and therapeutic effects in rabbit VX2 liver tumor.2023Drug deliveryFree full text
  45. Adipose distribution patterns as prognostic factors in patients with HCC: A systematic review and meta-analysis.2023European journal of radiology
  46. Early alpha-fetoprotein response predicts prognosis of immune checkpoint inhibitor and targeted therapy for hepatocellular carcinoma: a systematic review with meta-analysis.2023Expert review of gastroenterology & hepatology
  47. Performance of GALAD score and serum biomarkers for detecting NAFLD-related HCC: a systematic review and network meta-analysis.2023Expert review of gastroenterology & hepatology
  48. Tenofovir versus entecavir on the prognosis of hepatitis B virus-related hepatocellular carcinoma: a systematic review and meta-analysis.2023Expert review of gastroenterology & hepatology
  49. The association of fatty liver and risk of hepatocellular carcinoma in HBV or HCV infected individuals: a systematic review and meta-analysis.2023Expert review of gastroenterology & hepatology
  50. Development and validation of prognostic risk prediction models for hepatocellular carcinoma patients treated with immune checkpoint inhibitors based on a systematic review and meta-analysis of 47 cohorts.2023Frontiers in immunologyFree full text
  51. New techniques: a roadmap for the development of HCC immunotherapy.2023Frontiers in immunologyFree full text
  52. HMGCL-induced β-hydroxybutyrate production attenuates hepatocellular carcinoma via DPP4-mediated ferroptosis susceptibility.2023Hepatology internationalFree full text
  53. Identification of the most effective subgroup of advanced hepatocellular carcinoma from immune checkpoint blocker treatment: a meta-analysis.2023Immunotherapy
  54. Efficacy and security of tumor vaccines for hepatocellular carcinoma: a systemic review and meta-analysis of the last 2 decades.2023Journal of cancer research and clinical oncologyFree full text
  55. Construction of an anoikis‒related prognostic signature to predict immunotherapeutic response and prognosis in hepatocellular carcinoma.2023Journal of cancer research and clinical oncologyFree full text
  56. Gastrointestinal: Pitfalls of an abruptly elevated alpha-fetoprotein in a chronic hepatitis B carrier.2023Journal of gastroenterology and hepatology
  57. The Association of Glycemic Index, Glycemic Load, and Daily Carbohydrates Intake with the Risk of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.2023Nutrition and cancer
  58. Decreased GPX3 mRNA level in peripheral blood mononuclear cells is associated with HBV-related hepatocellular carcinoma.2023Transactions of the Royal Society of Tropical Medicine and Hygiene
  59. MYC Promotes LDHA Expression through MicroRNA-122-5p to Potentiate Glycolysis in Hepatocellular Carcinoma.2022Analytical cellular pathology (Amsterdam)Free full text
  60. The influence of transarterial chemoembolization on serum levels of soluble programed cell death ligand-1 in advanced hepatocellular carcinoma patients.2022Asia-Pacific journal of clinical oncology
  61. IGF2BP3-NRF2 axis regulates ferroptosis in hepatocellular carcinoma.2022Biochemical and biophysical research communications
  62. Prognostic value of soluble programmed cell death-1 (sPD-1) and soluble programmed cell death ligand-1 (sPD-L1) for hepatocellular carcinoma: a systematic review and meta-analysis.2022Cancer immunology, immunotherapy : CIIFree full text
  63. The causal relationship between white blood cell counts and hepatocellular carcinoma: a Mendelian randomization study.2022European journal of medical researchFree full text
  64. MRI-based preoperative markers combined with narrow-margin hepatectomy result in higher early recurrence.2022European journal of radiologyRCT
  65. The Prognostic Value of Natural Killer Cells and Their Receptors/Ligands in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.2022Frontiers in immunologyFree full text
  66. Management of hepatocellular carcinoma patients with portal vein tumor thrombosis: A narrative review.2022Hepatobiliary & pancreatic diseases international : HBPD INT
  67. Prognostic potential of the small GTPase Ran and its methylation in hepatocellular carcinoma.2022Hepatobiliary & pancreatic diseases international : HBPD INT
  68. Integrin alpha 6 is upregulated and drives hepatocellular carcinoma progression through integrin α6β4 complex.2022International journal of cancerFree full text
  69. Clinical benefits of direct-acting antivirals therapy in hepatitis C virus patients with hepatocellular carcinoma: A systematic review and meta-analysis.2022Journal of gastroenterology and hepatology
  70. Dual roles of WISP2 in the progression of hepatocellular carcinoma: implications of the fibroblast infiltration into the tumor microenvironment.2021AgingFree full text
  71. ST8SIA6-AS1 promotes the development of hepatocellular carcinoma cells through miR-338-3p/NONO Axis.2021Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  72. 5-Aza-2'-deoxycytidine may enhance the frequency of T regulatory cells from CD4+ naïve T cells isolated from the peripheral blood of patients with chronic HBV infection.2021Expert review of clinical immunology
  73. Viral Status and Efficacy of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis.2021Frontiers in immunologyFree full text
  74. Sex and regional disparities in incidence of hepatocellular carcinoma in autoimmune hepatitis: a systematic review and meta-analysis.2021Hepatology international
  75. Effects of hypoxia-inducible factor-1α and hypoxia-inducible factor-2α overexpression on hepatocellular carcinoma survival: A systematic review with meta-analysis.2021Journal of gastroenterology and hepatology
  76. Hypermethylation of secreted frizzled related protein 2 gene promoter serves as a noninvasive biomarker for HBV-associated hepatocellular carcinoma.2021Life sciences
  77. Tumor attenuation and quantitative analysis of perfusion parameters derived from tri-phasic CT scans in hepatocellular carcinoma: Relationship with histological grade.2021MedicineFree full text
  78. Repeated postoperative adjuvant TACE after curative hepatectomy improves outcomes of patients with HCC.2021Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy
  79. Value of perfusion parameters histogram analysis of triphasic CT in differentiating intrahepatic mass forming cholangiocarcinoma from hepatocellular carcinoma.2021Scientific reportsFree full text
  80. LncRNA ZEB1-AS1 regulates hepatocellular carcinoma progression by targeting miR-23c.2021World journal of surgical oncologyFree full text
All its trials on ClinicalTrials.gov, any status8
  1. Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative ResectionRecruitingNCT06454578Lead sponsorPhase 2Start 2024-07
  2. Establishment of Scoring Model for Early and Differential Diagnosis of Intrahepatic CholangiocarcinomaStatus unknownNCT05327907Lead sponsorStart 2020-11
  3. Efficacy of TACE With Endoscopic Therapy for Unresectable Hepatocellular CarcinomaCompletedNCT05017922Lead sponsorN/AStart 2017-01
  4. Perioperative Risk of Immunotherapy Based Neoadjuvant and Conversion Therapy for Hepatocellular CarcinomaStatus unknownNCT06571396Lead sponsorStart 2014-04
  5. TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal HypertensionNot yet recruitingNCT07350070Study sitePhase 2Start 2025-12
  6. Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High RiskNot yet recruitingNCT07010588Study siteN/AStart 2025-06
  7. A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)Active, not recruitingNCT04344158Study sitePhase 3Start 2020-08
  8. TACE Combinated With Sorafenib in Treating Patients With Unresectable Hepatocellular CarcinomaStatus unknownNCT01605734Study sitePhase 2Start 2012-07

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 80 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.8%.

Papers led
80
2021–2025
Trials led
41
any status, ClinicalTrials.gov
Open trials led
15
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 7720212022: 141420222023: 202020232024: 161620242025: 18182025

8 hospitals in Jinan for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 15

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Safety and Efficacy of Leucine-Restricted Diet Combined With Chemotherapy and Immunotherapy in Advanced Gastric Cancer
    Phase
    Phase 2
    Started
    2026-01
    Registry
    NCT07537348

    Age 18 years to 70 years (registered criteria)

    Led by Qilu Hospital of Shandong UniversityJinan

  2. Recruiting
    Safety and Efficacy of Leucine-Restricted Diet Combined With Neoadjuvant Chemotherapy and Immunotherapy in Gastric Cancer
    Phase
    Phase 2
    Started
    2026-01
    Registry
    NCT07537361

    Age 18 years to 70 years (registered criteria)

    Led by Qilu Hospital of Shandong UniversityJinan

  3. Recruiting
    Comparison of Double-tract and Tubular Gastric Anastomosis in Proximal Gastric Cancer
    Phase
    N/A
    Started
    2026-05
    Registry
    NCT07635836

    Age 18 years to 75 years (registered criteria)

    Led by Qilu Hospital of Shandong UniversityJinan

  4. Recruiting
    Exploring the Difference Between Gastric Cardia Cancer and Non-cardia Gastric Cancer Based on Multiomics
    Phase
    Not given
    Started
    2024-03
    Registry
    NCT05812287

    Age 18 years to 75 years (registered criteria)

    Led by Qilu Hospital of Shandong UniversityJinan

  5. Recruiting
    Integrative Analysis of Exosome-Mediated Single-Cell Transcriptomics and Proteomics in Gastric Cardia Cancer
    Phase
    Not given
    Started
    2024-12
    Registry
    NCT06702891

    Age 18 years to Not stated (registered criteria)

    Led by Qilu Hospital of Shandong UniversityJinan

  6. Recruiting
    First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
    Phase
    Phase 2
    Started
    2024-10
    Registry
    NCT06730373

    Age 18 years to 75 years (registered criteria)

    Led by Qilu Hospital of Shandong University; 7 listed hospitals as study sitesJinan, Linyi, Qingdao, Yantai, Zhengzhou, Zibo

  7. Recruiting
    Safety and Efficacy of Traction Robot-assisted Endoscopic Submucosal Dissection for Early Gastric Cancer
    Phase
    N/A
    Started
    2024-12
    Registry
    NCT06748352

    Age 18 years to 80 years (registered criteria)

    Led by Qilu Hospital of Shandong UniversityJinan

  8. Recruiting
    Intraperitoneal Immune Checkpoint Inhibitors and Zoledronic Acids for Gastric Cancer Malignant Ascites
    Phase
    Phase 1/Phase 2
    Started
    2024-09
    Registry
    NCT06759064

    Age 18 years to 75 years (registered criteria)

    Led by Qilu Hospital of Shandong UniversityJinan

  9. Recruiting
    First-Line and Neoadjuvant Immunotherapy for Gastric Cancer
    Phase
    Not given
    Started
    2022-01
    Registry
    NCT06727981

    Age 18 years to 100 years (registered criteria)

    Led by Qilu Hospital of Shandong UniversityJinan

  10. Not yet recruiting
    One-Click Autofocus Versus Segmented Focus in Gastric Endoscopy
    Phase
    N/A
    Started
    2026-06
    Registry
    NCT07664813

    Age 18 years to Not stated (registered criteria)

    Led by Qilu Hospital of Shandong UniversityJinan

  11. Not yet recruiting
    Multi-center Prospective Validation of Real-Time AI-EGGIM System
    Phase
    Not given
    Started
    2026-11
    Registry
    NCT07915843

    Age not stated (registered criteria)

    Led by Qilu Hospital of Shandong UniversityJinan

  12. Not yet recruiting
    Evaluation of the Efficacy and Safety of Indocyanine Green Tracing in 3D Fluorescent Laparoscopic Lymph Node Dissection for Gastric Cancer
    Phase
    N/A
    Started
    2024-05
    Registry
    NCT06421220

    Age 18 years to 75 years (registered criteria)

    Led by Qilu Hospital of Shandong UniversityJinan

  13. Enrolling by invitation
    Early Postoperative Intervention in Gastric Cancer Patients
    Phase
    N/A
    Started
    2026-02
    Registry
    NCT07444099

    Age 18 years to 80 years (registered criteria)

    Led by Qilu Hospital of Shandong UniversityJinan

  14. Enrolling by invitation
    Safety and Efficacy of Leucine-Restricted Diet in Gastric Cancer
    Phase
    Phase 1
    Started
    2025-10
    Registry
    NCT07488312

    Age 18 years to 70 years (registered criteria)

    Led by Qilu Hospital of Shandong UniversityJinan

  15. Enrolling by invitation
    Prolonged Extubation in Gastric Cancer With OSA
    Phase
    Not given
    Started
    2023-01
    Registry
    NCT07362706

    Age 18 years to 85 years (registered criteria)

    Led by Qilu Hospital of Shandong UniversityJinan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesEarly detection & endoscopyPeritoneal spread & advanced diseaseImmunotherapy & targeted drugs
Departments in papersGastroenterology / hepatologyPathology / laboratory medicineSurgery (general/hepatobiliary/pancreatic)Medical oncology
Papers it led80
  1. LINC 02086, a novel biomarker for early detection of gastric cancer and a target for cancer therapy.2026Cell death and differentiation
  2. OR2T6 modulates autophagy through the PPP3CA-mediated pathways to suppress gastric cancer.2026Cell death and differentiation
  3. Safety and efficacy of traction robot-assisted endoscopic submucosal dissection for early gastric cancer: a randomized pilot trial.2026EndoscopyRCT
  4. Genomic landscape of paired primary and peritoneal metastatic lesions in gastric cancer highlights evolutionary dynamics and mutational drivers.2026Journal of advanced researchFree full text
  5. Precise Identification of Gastric Cancer Pathological Differentiation Based on Hyperspectral Imaging and Lightweight Deep Learning Models.2026Journal of biophotonics
  6. High sodium intake: a silent killer driving global gastric cancer burden.2025BMC cancerFree full text
  7. Deep learning-aided optical biopsy achieves whole-chain diagnosis of Correa cascade of gastric cancer: a prospective study.2025BMC medicineFree full text
  8. Associations Between Gastroenteropancreatic Neuroendocrine Neoplasms and Inflammatory Factors: Insights From a Two-Sample Mendelian Randomization Analysis.2025Canadian journal of gastroenterology & hepatologyFree full text
  9. N6-methyladenosine-regulated exosome biogenesis orchestrates an immunosuppressive pre-metastatic niche in gastric cancer peritoneal metastasis.2025Cancer communications (London, England)Free full text
  10. Simvastatin inhibits PD-L1 via ILF3 to induce ferroptosis in gastric cancer cells.2025Cell death & diseaseFree full text
  11. SP-1-activated LINC01016 overexpression promotes gastric cancer invasion and metastasis through inhibiting EIF4A3-mediated MMP9 mRNA decay.2025Cell death & diseaseFree full text
  12. ncRNA-mediated ITGB1 upregulation correlates with poor prognosis and tumor-immune infiltration in gastric cancer.2025European journal of medical researchFree full text
  13. Hedyotis diffusa Willd.-Scutellaria barbata D.Don herb pair induces ferroptosis in gastric cancer by inhibiting the PI3K/AKT/HIF-1α pathway.2025Fitoterapia
  14. Survival and multi-omics analysis of immunotherapy-based conversion treatment for initially unresectable gastric cancer.2025Frontiers in immunologyFree full text
  15. LncRNAs in serum-derived extracellular vesicles are potential biomarker and correlated with immune infiltration in gastric cancer.2025Frontiers in immunologyFree full text
  16. Development and validation of a machine learning model for predicting immune checkpoint inhibitor efficacy in advanced gastric cancer using dynamic changes in peripheral blood clinlabomics data: a retrospective multicenter cohort study.2025Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  17. Optical enhancement with magnification versus white-light endoscopy for detecting gastric intestinal metaplasia and neoplasia: a randomized controlled trial.2025Gastrointestinal endoscopyRCT
  18. Vagus Nerve Preservation for Early Distal Gastric Cancer With Monitoring and Indocyanine Green Labeling: A Randomized Clinical Trial.2025JAMA surgeryRCTFree full text
  19. Comparative analysis of gastrectomy vs endoscopic therapy for T1b gastric cancer: long-term outcomes from a population-based propensity score matched cohort study.2025Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  20. Assessment of intestinal metaplasia at the lesser curvature guides mapping biopsies strategy.2025Scandinavian journal of gastroenterology
  21. Association between gastric polyps and decreased bone mineral density in patients with chronic gastritis.2025Scientific reportsFree full text
  22. Application of in vivo traction-assisted resection of large gastric mucosal lesions: a case series (with video).2025Surgical endoscopy
  23. Timing and clinical significance of chemotherapy in patients with resected gastric adenocarcinoma: a population-based cohort study.2025The oncologistFree full text
  24. Development and validation of a predictive model for submucosal fibrosis in patients with early gastric cancer undergoing endoscopic submucosal dissection: experience from a large tertiary center.2024Annals of medicineFree full text
  25. The Impact of Transcriptional Profiling Cadherin Family and Therapeutic Approaches of Gastric Cancer: A Translational Outlook on Multi-omics Data Analysis.2024Applied biochemistry and biotechnology
  26. Efficacy, safety, and biomarker analysis of first-line immune checkpoint inhibitors with chemotherapy versus chemotherapy for advanced gastric cancer: a multicenter, retrospective cohort study.2024BMC medicineFree full text
  27. Dual PI3K/mTOR inhibitor PF-04979064 regulates tumor growth in gastric cancer and enhances drug sensitivity of gastric cancer cells to 5-FU.2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  28. Harnessing cytokines to optimize chimeric antigen receptor-T cell therapy for gastric cancer: Current advances and innovative strategies.2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  29. CMYC-initiated HNF1A-AS1 overexpression maintains the stemness of gastric cancer cells.2024Cell death & diseaseFree full text
  30. Molecular characterization and clinical relevance of metabolic signature subtypes in gastric cancer.2024Cell reports
  31. Advances in Endoscopic Diagnosis and Treatment of Gastric Neuroendocrine Neoplasms.2024Digestive diseases and sciences
  32. A modified endoscopic full-thickness resection technique: double traction-assisted resection.2024EndoscopyFree full text
  33. Endoscopic submucosal dissection of early gastric angle cancer by using a simplified robot-assisted device for traction.2024EndoscopyFree full text
  34. Identification of necroptosis-associated miRNA signature for predicting prognosis and immune landscape in stomach adenocarcinoma.2024Experimental cell research
  35. Expression and clinical value of CXCR4 in high grade gastroenteropancreatic neuroendocrine neoplasms.2024Frontiers in endocrinologyFree full text
  36. Disruption of the gastric epithelial barrier in Correa's cascade: Clinical evidence via confocal endomicroscopy.2024Helicobacter
  37. PIN1P1 is activated by CREB1 and promotes gastric cancer progression via interacting with YBX1 and upregulating PIN1.2024Journal of cellular and molecular medicineFree full text
  38. Single-cell profiling reveals altered immune landscape and impaired NK cell function in gastric cancer liver metastasis.2024Oncogene
  39. Proteomic and serological markers for diagnosing cardia gastric cancer and precursor lesions in a Chinese population.2024Scientific reportsFree full text
  40. Neoadjuvant Therapy with Immune Checkpoint Inhibitors in Gastric Cancer: A Systematic Review and Meta-Analysis.2023Annals of surgical oncology
  41. Coexistence of early gastric cancer and benign submucosal lesions mimic invasive cancer: a retrospective multicenter experience.2023BMC gastroenterologyFree full text
  42. Goblet cells segmentation from confocal laser endomicroscopy with an improved U-Net.2023Biomedical physics & engineering express
  43. Fusobacterium nucleatum-induced exosomal HOTTIP promotes gastric cancer progression through the microRNA-885-3p/EphB2 axis.2023Cancer scienceFree full text
  44. POU5F1 promotes the proliferation, migration, and invasion of gastric cancer cells by reducing the ubiquitination level of TRAF6.2023Cell death & diseaseFree full text
  45. PTPN14 promotes gastric cancer progression by PI3KA/AKT/mTOR pathway.2023Cell death & diseaseFree full text
  46. TRIM44 regulates tumor immunity in gastric cancer through LOXL2-dependent extracellular matrix remodeling.2023Cellular oncology (Dordrecht, Netherlands)Free full text
  47. Effect of liver metastasis on the efficacy of immune checkpoint inhibitors in cancer patients: a systemic review and meta-analysis.2023Clinical & experimental metastasis
  48. Efficacy of anti-programmed cell death protein 1 monoclonal antibody combined with bevacizumab and/or Pseudomonas aeruginosa injection in transplanted tumor of mouse forestomach carcinoma cell gastric cancer in mice and its mechanism in reg2023Clinical and experimental immunology
  49. Serum extracellular vesicles with NSD1 and FBXO7 mRNA as novel biomarkers for gastric cancer.2023Clinical biochemistry
  50. A novel extracorporeal accessory traction device for gastric endoscopic submucosal dissection.2023EndoscopyFree full text
  51. HRCT1, negatively regulated by miR-124-3p, promotes tumor metastasis and the growth of gastric cancer by activating the ERBB2-MAPK pathway.2023Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  52. Cardia and non-cardia gastric cancer risk associated with Helicobacter pylori in East Asia and the West: A systematic review, meta-analysis, and estimation of population attributable fraction.2023Helicobacter
  53. Transmission routes and patterns of helicobacter pylori.2023Helicobacter
  54. CircHIPK3 contributes to cisplatin resistance in gastric cancer by blocking autophagy-dependent ferroptosis.2023Journal of cellular physiology
  55. A rare case of gastric adenocarcinoma with enteroblastic differentiation presenting as pancreatic hepatoid adenocarcinoma metastases.2023Journal of hepato-biliary-pancreatic sciences
  56. Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer.2023Nature communicationsFree full text
  57. Diagnostic role and prognostic value of tumor markers in high-grade gastro-enteropancreatic neuroendocrine neoplasms.2023Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  58. Identification and validation of key genes associated with pathogenesis and prognosis of gastric cancer.2023PeerJFree full text
  59. Color-guided deformable convolution network for intestinal metaplasia severity classification using endoscopic images.2023Physics in medicine and biology
  60. Ox-LDL-mediated ILF3 overexpression in gastric cancer progression by activating the PI3K/AKT/mTOR signaling pathway.2022AgingFree full text
  61. Metabolism reprogramming signature associated with stromal cells abundance in tumor microenvironment improve prognostic risk classification for gastric cancer.2022BMC gastroenterologyFree full text
  62. Long noncoding RNA lnc-LEMGC combines with DNA-PKcs to suppress gastric cancer metastasis.2022Cancer letters
  63. Upregulation of CRABP2 by TET1-mediated DNA hydroxymethylation attenuates mitochondrial apoptosis and promotes oxaliplatin resistance in gastric cancer.2022Cell death & diseaseFree full text
  64. Linc01133 contributes to gastric cancer growth by enhancing YES1-dependent YAP1 nuclear translocation via sponging miR-145-5p.2022Cell death & diseaseFree full text
  65. lncRNA THAP7-AS1, transcriptionally activated by SP1 and post-transcriptionally stabilized by METTL3-mediated m6A modification, exerts oncogenic properties by improving CUL4B entry into the nucleus.2022Cell death and differentiationFree full text
  66. Double-endoscope assisted endoscopic submucosal dissection for treating gastric neuroendocrine tumor.2022Endoscopy
  67. CPNE1 silencing inhibits cell proliferation and accelerates apoptosis in human gastric cancer.2022European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
  68. Effects of enhanced education for patients with the Helicobacter pylori infection: A systematic review and meta-analysis.2022Helicobacter
  69. Association of microRNA polymorphisms with gastric cancer risk in the North Chinese Han population.2022Journal of cancer research and therapeutics
  70. Poor oral hygiene behavior is associated with an increased risk of gastric cancer: A population-based case-control study in China.2022Journal of periodontology
  71. Study on the application of preoperative three-dimensional CT angiography of perigastric arteries in laparoscopic radical gastrectomy.2022Scientific reportsFree full text
  72. A novel flexible auxiliary single-arm transluminal endoscopic robot facilitates endoscopic submucosal dissection of gastric lesions (with video).2022Surgical endoscopy
  73. Salivary Fusobacterium nucleatum serves as a potential diagnostic biomarker for gastric cancer.2022World journal of gastroenterologyFree full text
  74. Proctotomy leak following laparoscopic total gastrectomy with transrectal specimen extraction for gastric cancer: a case report.2021BMC surgeryFree full text
  75. Gastroenteropancreatic neuroendocrine neoplasms G3: Novel insights and unmet needs.2021Biochimica et biophysica acta. Reviews on cancer
  76. Screening for upper gastrointestinal cancers with magnetically controlled capsule gastroscopy: a feasibility study.2021Endoscopy
  77. A Signature-Based Classification of Gastric Cancer That Stratifies Tumor Immunity and Predicts Responses to PD-1 Inhibitors.2021Frontiers in immunologyFree full text
  78. Elevated ZBTB7A expression in the tumor invasive front correlates with more tumor budding formation in gastric adenocarcinoma.2021Journal of cancer research and clinical oncologyFree full text
  79. MiR-19a/miR-96-mediated low expression of KIF26A suppresses metastasis by regulating FAK pathway in gastric cancer.2021Oncogene
  80. Influence of Sedation on the Detection Rate of Early Cancer and Precancerous Lesions During Diagnostic Upper Gastrointestinal Endoscopies: A Multicenter Retrospective Study.2021The American journal of gastroenterology
All its trials on ClinicalTrials.gov, any status46
  1. Safety and Efficacy of Leucine-Restricted Diet Combined With Chemotherapy and Immunotherapy in Advanced Gastric CancerRecruitingNCT07537348Lead sponsorPhase 2Start 2026-01
  2. Multi-center Prospective Validation of Real-Time AI-EGGIM SystemNot yet recruitingNCT07915843Lead sponsorStart 2026-11
  3. Comparison of Double-tract and Tubular Gastric Anastomosis in Proximal Gastric CancerRecruitingNCT07635836Lead sponsorN/AStart 2026-05
  4. Safety and Efficacy of Leucine-Restricted Diet Combined With Neoadjuvant Chemotherapy and Immunotherapy in Gastric CancerRecruitingNCT07537361Lead sponsorPhase 2Start 2026-01
  5. Early Postoperative Intervention in Gastric Cancer PatientsEnrolling by invitationNCT07444099Lead sponsorN/AStart 2026-02
  6. Safety and Efficacy of Leucine-Restricted Diet in Gastric CancerEnrolling by invitationNCT07488312Lead sponsorPhase 1Start 2025-10
  7. Exploring the Difference Between Gastric Cardia Cancer and Non-cardia Gastric Cancer Based on MultiomicsRecruitingNCT05812287Lead sponsorStart 2024-03
  8. Integrative Analysis of Exosome-Mediated Single-Cell Transcriptomics and Proteomics in Gastric Cardia CancerRecruitingNCT06702891Lead sponsorStart 2024-12
  9. Evaluation of the Efficacy and Safety of Indocyanine Green Tracing in 3D Fluorescent Laparoscopic Lymph Node Dissection for Gastric CancerNot yet recruitingNCT06421220Lead sponsorN/AStart 2024-05
  10. Intraperitoneal Immune Checkpoint Inhibitors and Zoledronic Acids for Gastric Cancer Malignant AscitesRecruitingNCT06759064Lead sponsorPhase 1/Phase 2Start 2024-09
  11. First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)RecruitingNCT06730373Lead sponsorPhase 2Start 2024-10
  12. Prolonged Extubation in Gastric Cancer With OSAEnrolling by invitationNCT07362706Lead sponsorStart 2023-01
  13. First-Line and Neoadjuvant Immunotherapy for Gastric CancerRecruitingNCT06727981Lead sponsorStart 2022-01
  14. Postoperative Adjuvant Therapy for Stage II-III Gastric CancerActive, not recruitingNCT06609759Lead sponsorStart 2024-01
  15. Minimal Residual Disease-guided Adjuvant Therapy for Gastric CancerActive, not recruitingNCT06157216Lead sponsorN/AStart 2023-10
  16. First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric CancerActive, not recruitingNCT05586061Lead sponsorPhase 2Start 2023-02
  17. Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior ImmunotherapyActive, not recruitingNCT05585580Lead sponsorPhase 2Start 2023-03
  18. Neoadjuvant Immunotherapy for Resectable Gastric CancerCompletedNCT03878472Lead sponsorPhase 2Start 2019-04
  19. Significance of Circulating Tumor Cells in the Treatment of Gastric and Rectal CancerCompletedNCT02955173Lead sponsorN/AStart 2016-12
  20. One-Click Autofocus Versus Segmented Focus in Gastric EndoscopyNot yet recruitingNCT07664813Lead (inferred)N/AStart 2026-06
  21. Safety and Efficacy of Traction Robot-assisted Endoscopic Submucosal Dissection for Early Gastric CancerRecruitingNCT06748352Lead (inferred)N/AStart 2024-12
  22. AI-assisted White Light Endoscopy to Identify the Kimura-Takemoto Classification of Atrophic GastritisStatus unknownNCT05916014Lead (inferred)Start 2023-06
  23. Artificial Intelligence Confocal Laser Endomicroscopy for Real-time Assessment of Gastric Cancer Risk.Status unknownNCT05459428Lead (inferred)Start 2022-05
  24. Artificial Intelligence-assisted Confocal Laser Endomicroscopy Identification of Intestinal Metaplasia SeverityStatus unknownNCT05462743Lead (inferred)Start 2022-07
  25. Different Endoscopic Gastric Cancer Risk AssessmentsStatus unknownNCT05458388Lead (inferred)N/AStart 2022-07
  26. Automatic Evaluation of the Severity of Gastric Intestinal Metaplasia With Pathology Artificial Intelligence Diagnosis SystemStatus unknownNCT05447221Lead (inferred)Start 2022-08
  27. AQCS for Detection of Early Cancer and Precancerous Lesions on Upper Gastrointestinal TractCompletedNCT04720924Lead (inferred)N/AStart 2021-01
  28. Application of Artificial Intelligence for Early Diagnosis of Gastric Cancer During Optical Enhancement Magnifying EndoscopyStatus unknownNCT04563416Lead (inferred)Start 2020-07
  29. The Diagnostic Ability of White Light Endoscopy and Magnifying Endoscopy With Optical Enhancement SystemStatus unknownNCT04411589Lead (inferred)N/AStart 2020-05
  30. Quality Control of Esophagogastroduodenoscopy Using Real-time EGD Auxiliary SystemCompletedNCT03883035Lead (inferred)N/AStart 2019-03
  31. Medical Consortium for Screening Upper Gastrointestinal Cancers With Magnetically Controlled Capsule GastroscopyStatus unknownNCT04032353Lead (inferred)N/AStart 2018-12
  32. Endoscopic Ultrasound-guided Needle-based Confocal Laser Endomicroscopy for Diagnosis of Gastric Subepithelial TumorsCompletedNCT02936986Lead (inferred)Start 2016-05
  33. Difference of Gastric Microbiota in the Process of Correa's Model.Status unknownNCT02833363Lead (inferred)Start 2016-07
  34. High Definition Endoscopy and Optic Enhancement Endoscopy in Gastric Neoplasia: A Prospective StudyStatus unknownNCT02863965Lead (inferred)Start 2016-03
  35. PCLE for the Diagnosis of Gastric Intestinal Metaplasia, Intraepithelial Neoplasia, and CarcinomaStatus unknownNCT02515721Lead (inferred)N/AStart 2014-07
  36. Association Between Confocal Laser Endomicroscopic (CLE) Features and Gastric Mucosal MicrobiomeStatus unknownNCT02063932Lead (inferred)Start 2013-12
  37. New Classification of Stomach Using Probe-based Confocal Laser EndomicroscopyCompletedNCT01896310Lead (inferred)Start 2013-06
  38. Artificial Intelligence for Determination of Gastroscopy Surveillance IntervalsStatus unknownNCT05631015Lead (inferred)Start 2012-01
  39. Confocal Laser Endomicroscopy for the Diagnosis of Gastric Intestinal Metaplasia, Intraepithelial Neoplasia, and CarcinomaStatus unknownNCT01642797Lead (inferred)N/AStart 2012-08
  40. Confocal Laser Endomicroscopy for in Vivo Molecular Imaging of Gastric Cancer by Targeting MG7-AgCompletedNCT01366586Lead (inferred)Start 2011-05
  41. Detection of Early Gastric Cancers Using Confocal Laser EndomicroscopyCompletedNCT00851305Lead (inferred)N/AStart 2008-08
  42. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.TerminatedNCT05111626Study sitePhase 3Start 2022-03
  43. Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETsCompletedNCT04852679Study sitePhase 3Start 2021-05
  44. Capnographic Monitoring in Gastrointestinal Endoscopy for Elderly PatientsCompletedNCT05030870Study siteN/AStart 2021-09
  45. Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric CancerTerminatedNCT02867839Study sitePhase 3Start 2017-04
  46. S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Calcium Plus Oxaliplatin as Perioperative Chemotherapy for Advanced Gastric CarcinomaCompletedNCT01364376Study siteN/AStart 2011-06

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatoblastoma

肝母细胞瘤

Led no English-language PubMed papers on hepatoblastoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Jinan for hepatoblastoma88 hospitals in China for hepatoblastoma

No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led 1 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

8 hospitals in Jinan for retinoblastoma196 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Chordoma

脊索瘤

Led no English-language PubMed papers on chordoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Jinan for chordoma88 hospitals in China for chordoma

No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. [Primary extra-axial chordoma of distal fibula: report of a case].2019Zhonghua bing li xue za zhi = Chinese journal of pathology

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 16 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
16
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 7720222023: 3320232024: 0020242025: 552025

24 hospitals in Jinan for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics

Over half of these papers are lab or animal studies.

Papers it led16
  1. Dual-release 3D-printed porous Ti-6Al-4V implant with drug-eluting photothermal micro-nanotopographies: combating osteosarcoma recurrence, infections, and enhancing osteogenesis.2026Biomaterials
  2. N6-Methyladenosine modification mediated by METTL3 promotes DNA-PKcs expression to induce anlotinib resistance in osteosarcoma.2025Clinical and translational medicine
  3. CUDC-907 inhibits osteosarcoma through upregulation of PTX3 and inhibition of PI3K-AKT signaling.2025European journal of pharmacology
  4. Gene signatures of m5C regulators may predict prognosis and immunity status of patients with Ewing's sarcoma.2025International immunopharmacology
  5. Ghrelin increases cis-platinum resistance and promotes aggressiveness of osteosarcoma by activating AKT and Wnt/β-catenin pathways.2025Journal of orthopaedic surgery and research
  6. Osteopontin derived from hypoxia-induced M2 macrophages promotes osteosarcoma progression through modulation of EGR3/ISG15 signaling and RIG-I expression.2025Journal of translational medicine
  7. DEPDC1 as a crucial factor in the progression of human osteosarcoma.2023Cancer medicine
  8. Eicosapentaenoic acid enhances the sensitivity of osteosarcoma to cisplatin by inducing ferroptosis through the DNA-PKcs/AKT/NRF2 pathway and reducing PD-L1 expression to attenuate immune evasion.2023International immunopharmacology
  9. Piperine improves the sensitivity of osteosarcoma cells to doxorubicin by inducing apoptosis and inhibiting the PI3K/AKT/GSK-3β pathway.2023Journal of orthopaedic surgery and research
  10. STEAP2 promotes osteosarcoma progression by inducing epithelial-mesenchymal transition via the PI3K/AKT/mTOR signaling pathway and is regulated by EFEMP2.2022Cancer biology & therapy
  11. SIRT2 promotes the viability, invasion and metastasis of osteosarcoma cells by inhibiting the degradation of Snail.2022Cell death & disease
  12. LINC00313 facilitates osteosarcoma carcinogenesis and metastasis through enhancing EZH2 mRNA stability and EZH2-mediated silence of PTEN expression.2022Cellular and molecular life sciences : CMLS
  13. Identification of Key Genes and miRNAs Affecting Osteosarcoma Based on Bioinformatics.2022Disease markers
  14. In situ Co-Delivery of Doxorubicin and Cisplatin by Injectable Thermosensitive Hydrogels for Enhanced Osteosarcoma Treatment.2022International journal of nanomedicine
  15. Discovery and Characterization of Intercondylar Transphyseal Complexes and their Oncological Significance in Transphyseal Extension of Pediatric Osteosarcoma.2022Orthopaedic surgery
  16. Asiaticoside reverses M2 phenotype macrophage polarization-evoked osteosarcoma cell malignant behaviour by TRAF6/NF-κB inhibition.2022Pharmaceutical biology
Earlier papers (2016–2020)18
  1. Wnt/β‑catenin signaling modulates piperine‑mediated antitumor effects on human osteosarcoma cells.2020Molecular medicine reports
  2. CD271 antibody-functionalized HGNs for targeted photothermal therapy of osteosarcoma stem cells.2020Nanotechnology
  3. Maternal embryonic leucine zipper kinase serves as a poor prognosis marker and therapeutic target in osteosarcoma.2020Oncology reports
  4. Long non-coding RNA TUSC7 suppresses osteosarcoma by targeting miR-211.2019Bioscience reports
  5. MicroRNA-99b predicts clinical outcome of osteosarcoma and suppresses tumor cell proliferation, migration and invasion.2019Diagnostic pathology
  6. Downregulation of UBE2T can enhance the radiosensitivity of osteosarcoma in vitro and in vivo.2019Epigenomics
  7. Anti-tumoral potential of MDA19 in human osteosarcoma via suppressing PI3K/Akt/mTOR signaling pathway.2018Bioscience reports
  8. MicroRNA-645 promotes metastasis of osteosarcoma via targeting tumor suppressor NM23 nucleoside diphosphate kinase 2.2018Clinical and experimental pharmacology & physiology
  9. Identifying osteosarcoma metastasis associated genes by weighted gene co-expression network analysis (WGCNA).2018Medicine
  10. MicroRNA‑34b promotes proliferation, migration and invasion of Ewing's sarcoma cells by downregulating Notch1.2018Molecular medicine reports
  11. Combined analysis of gene expression and genome binding profiles identified potential therapeutic targets of ciclopirox in Ewing sarcoma.2018Molecular medicine reports
  12. EWS-FLI1 positively regulates autophagy by increasing ATG4B expression in Ewing sarcoma cells.2017International journal of molecular medicine
  13. Fibulin-4 promotes osteosarcoma invasion and metastasis by inducing epithelial to mesenchymal transition via the PI3K/Akt/mTOR pathway.2017International journal of oncology
  14. Inhibition of autophagy and enhancement of endoplasmic reticulum stress increase sensitivity of osteosarcoma Saos-2 cells to cannabinoid receptor agonist WIN55,212-2.2016Cell biochemistry and function
  15. HER-2 expression in biopsy and surgical specimen on prognosis of osteosarcoma: A systematic review and meta-analysis of 16 studies.2016Medicine
  16. MicroRNA-181a promotes proliferation and inhibits apoptosis by suppressing CFIm25 in osteosarcoma.2016Molecular medicine reports
  17. Downregulation of DNA-PKcs suppresses P-gp expression via inhibition of the Akt/NF-κB pathway in CD133-positive osteosarcoma MG-63 cells.2016Oncology reports
  18. Diallyl trisulfide induces osteosarcoma cell apoptosis through reactive oxygen species-mediated downregulation of the PI3K/Akt pathway.2016Oncology reports
All its trials on ClinicalTrials.gov, any status1
  1. A Study of Sulfatinib on Relapsed or Refractory Drug Resistant OsteosarcomaNot yet recruitingNCT05590572Study sitePhase 1/Phase 2Start 2023-01

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led no English-language PubMed papers on gastrointestinal stromal tumour in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

4 hospitals in Jinan for gastrointestinal stromal tumour261 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 5 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 2220222023: 0020232024: 1120242025: 002025

9 hospitals in Jinan for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatricsRadiology / nuclear medicine

Over half of these papers are lab or animal studies.

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 1 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

5 hospitals in Jinan for Ewing sarcoma139 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 3 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.2%.

Papers led
3
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
4
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 222025

7 hospitals in Jinan for multiple myeloma178 hospitals in China for multiple myeloma

Open trials with this hospital 5

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Cardiac Toxicity and Prognostic Value of New Echocardiographic Indicators in the Treatment of Primary Multiple Myeloma
    Phase
    Not given
    Started
    2023-11
    Registry
    NCT06039735

    Age 18 years to 70 years (registered criteria)

    Led by Qilu Hospital of Shandong UniversityJinan

  2. Recruiting
    Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-03
    Registry
    NCT07529782

    Age Not stated to 18 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Hangzhou, Jinan, Suzhou, Tianjin

  3. Recruiting
    Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07555938

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 13 listed hospitals as study sitesGuangzhou, Hangzhou, Jinan, Kunming, Nanjing, Qingdao, Shanghai, Suzhou, Tianjin, Wenzhou, Wuhan

  4. Recruiting
    Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
    Phase
    Phase 3
    Started
    2022-09
    Registry
    NCT05243797

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changchun, Hangzhou, Jinan, Shanghai, Shenyang, Tianjin, Wenzhou, Wuhan, Zhengzhou

  5. Recruiting
    A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 3
    Started
    2022-10
    Registry
    NCT05552222

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 29 listed hospitals as study sitesBeijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shenzhen, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDiagnosis, MRD & riskRelapse & resistanceStem cell transplant
Papers it led3
  1. Real-world analysis of treatment patterns, effectiveness, and safety of daratumumab-based regimens in Chinese patients with newly diagnosed or relapsed/refractory multiple myeloma.2025BMC cancerFree full text
  2. Prognostic Implications of Thrombocytopenia in Chinese Patients With Newly Diagnosed Multiple Myeloma.2025Cancer medicineFree full text
  3. Refractory primary extramedullary plasmacytoma in kidney: a case report.2021The Journal of international medical researchFree full text
All its trials on ClinicalTrials.gov, any status12
  1. Cardiac Toxicity and Prognostic Value of New Echocardiographic Indicators in the Treatment of Primary Multiple MyelomaRecruitingNCT06039735Lead sponsorStart 2023-11
  2. Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple MyelomaRecruitingNCT07555938Study sitePhase 3Start 2026-06
  3. Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple MyelomaRecruitingNCT07529782Study sitePhase 1Start 2026-03
  4. Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell TransplantationRecruitingNCT05243797Study sitePhase 3Start 2022-09
  5. A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple MyelomaRecruitingNCT05552222Study sitePhase 3Start 2022-10
  6. A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and LenalidomideActive, not recruitingNCT06208150Study sitePhase 3Start 2024-01
  7. A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)Active, not recruitingNCT06464991Study sitePhase 3Start 2024-03
  8. A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple MyelomaStatus unknownNCT05236621Study sitePhase 3Start 2021-01
  9. SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological MalignanciesActive, not recruitingNCT04684108Study sitePhase 1Start 2021-11
  10. A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)CompletedNCT04939142Study sitePhase 3Start 2021-07
  11. Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 1)Status unknownNCT03975907Study sitePhase 1/Phase 2Start 2019-06
  12. Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)TerminatedNCT01947309Study siteStart 2013-11

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led 2 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 0.9%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
4
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

2 hospitals in Jinan for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia

Open trials with this hospital 4

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
    Phase
    Phase 2/Phase 3
    Started
    2025-01
    Registry
    NCT06764238

    Age 1 month to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 24 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenzhen, Suzhou, Tianjin, Wuhan, Xi'an

  2. Recruiting
    Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
    Phase
    Phase 2/Phase 3
    Started
    2025-03
    Registry
    NCT06882057

    Age 1 year to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 23 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Suzhou, Tianjin, Wuhan, Xi'an

  3. Recruiting
    Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
    Phase
    Phase 3
    Started
    2025-03
    Registry
    NCT07152041

    Age 1 month to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 20 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Shenzhen, Suzhou, Tianjin, Wuhan

  4. Recruiting
    Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
    Phase
    Not given
    Started
    2024-06
    Registry
    NCT06450067

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Jinan, Shanghai, Tianjin, Wuhan, Xuzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesChildren
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Blood disorders

Aplastic anaemia

再生障碍性贫血

Led 3 of the 412 English-language PubMed papers on aplastic anaemia with an author in mainland China, 2021–2025: 0.7%.

Papers led
3
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 2220242025: 002025

6 hospitals in Jinan for aplastic anaemia63 hospitals in China for aplastic anaemia

No open trial on aplastic anaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesChildrenThrombopoietin drugs
Departments in papersClinical trials / research unitGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophagocytic lymphohistiocytosis

噬血细胞性淋巴组织细胞增生症

Led 2 of the 399 English-language PubMed papers on haemophagocytic lymphohistiocytosis with an author in mainland China, 2021–2025: 0.5%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

2 hospitals in Jinan for haemophagocytic lymphohistiocytosis66 hospitals in China for haemophagocytic lymphohistiocytosis

No open trial on haemophagocytic lymphohistiocytosis lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesChildrenEBV & infection triggers
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Blood disorders

Beta thalassaemia

β 地中海贫血

Led no English-language PubMed papers on beta thalassaemia in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Jinan for beta thalassaemia157 hospitals in China for beta thalassaemia

No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led 2 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 0.7%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 0020242025: 002025

3 hospitals in Jinan for haemophilia A160 hospitals in China for haemophilia A

No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病

Led 7 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 1.4%.

Papers led
7
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 2220232024: 1120242025: 222025

3 hospitals in Jinan for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
    Phase
    Phase 2/Phase 3
    Started
    2024-07
    Registry
    NCT06413654

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xiamen, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesAntibodies & diagnosisAcute attack treatmentImaging
Departments in papersNeurologyRadiology / nuclear medicineNephrologyOphthalmology / neuro-ophthalmology
Papers it led7
  1. CFHR2 supplementation mitigates pathologies of neuromyelitis optica by regulating complement activation.2025Molecular therapy : the journal of the American Society of Gene Therapy
  2. MRI-based radiomics for differention of aquaporin 4-immunoglobulin G-positive neuromyelitis optic spectrum disorder and anti myelin oligodendrocyte glycoprotein immunoglobulin G-associated disorder.2025Multiple sclerosis and related disorders
  3. Factors associated with disease relapse rate in the Neuromyelitis optica spectrum disorder.2024The International journal of neuroscience
  4. Systemic inflammation response index is a useful indicator in distinguishing MOGAD from AQP4-IgG-positive NMOSD.2023Frontiers in immunologyFree full text
  5. Evaluation of microvascular changes in the retina and choriocapillaris in primary glaucoma and neuromyelitis optica spectrum disorder with optical coherence tomography angiography.2023Photodiagnosis and photodynamic therapy
  6. Effect of low-dose rituximab treatment on autoimmune nodopathy with anti-contactin 1 antibody.2022Frontiers in immunologyFree full text
  7. Neuromyelitis optica spectrum disorder with active replication of hepatitis B virus and seropositive anti-aquaporin-4 antibody: A case report.2021MedicineFree full text
All its trials on ClinicalTrials.gov, any status2
  1. A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)RecruitingNCT06413654Study sitePhase 2/Phase 3Start 2024-07
  2. A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum DisordersActive, not recruitingNCT06044350Study sitePhase 2Start 2023-08

Run the PubMed searchClinicalTrials.gov

Other diseases

Myasthenia gravis

重症肌无力

Led 6 of the 499 English-language PubMed papers on myasthenia gravis with an author in mainland China, 2021–2025: 1.2%.

Papers led
6
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 1120212022: 3320222023: 0020232024: 1120242025: 112025

4 hospitals in Jinan for myasthenia gravis93 hospitals in China for myasthenia gravis

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in Patients With Refractory Generalized Myasthenia Gravis
    Phase
    Phase 1
    Started
    2025-03
    Registry
    NCT06688435

    Age 18 years to 65 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteJinan

  2. Recruiting
    A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
    Phase
    Phase 3
    Started
    2021-07
    Registry
    NCT04951622

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jinan, Shanghai, Tianjin, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesStandard immunotherapyEye-only (ocular) myastheniaAntibodies & diagnosis
Departments in papersNeurology
Papers it led6
  1. Clinicopathological profiling and prognosis of idiopathic inflammatory myopathy overlapping with myasthenia gravis: a retrospective cohort study.2025Journal of neurology
  2. Rs1800629 polymorphism in TNF-alpha is associated with the susceptibility and initial short-term glucocorticoids efficacy in myasthenia gravis patients.2024Journal of neuroimmunology
  3. Optimization of the cut-offs in acetylcholine receptor antibodies and diagnostic performance in myasthenia gravis patients.2022Clinica chimica acta; international journal of clinical chemistry
  4. Safety of inactivated SARS-CoV-2 vaccines in myasthenia gravis: A survey-based study.2022Frontiers in immunologyFree full text
  5. Isolated dysarthria as the sole manifestation of myasthenia gravis: a case report.2022The Journal of international medical researchFree full text
  6. Complement C3 polymorphism is associated with the susceptibility of myasthenia gravis in Chinese adult patients.2021Journal of neuroimmunology
All its trials on ClinicalTrials.gov, any status7
  1. A Study to Evaluate the Safety and Preliminary Efficacy of SYS6020 CAR T-cells in Patients With Refractory Generalized Myasthenia GravisRecruitingNCT06688435Study sitePhase 1Start 2025-03
  2. A Study of Nipocalimab Administered to Adults With Generalized Myasthenia GravisRecruitingNCT04951622Study sitePhase 3Start 2021-07
  3. A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)Active, not recruitingNCT06456580Study sitePhase 3Start 2024-07
  4. A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia GravisActive, not recruitingNCT06298552Study sitePhase 3Start 2024-04
  5. A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia GravisActive, not recruitingNCT06558279Study sitePhase 3Start 2024-09
  6. Study of Telitacicept in Generalized Myasthenia GravisCompletedNCT05737160Study sitePhase 3Start 2023-03
  7. A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia GravisActive, not recruitingNCT05070858Study sitePhase 3Start 2021-12

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led 8 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 3.0%.

Papers led
8
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 1120222023: 1120232024: 3320242025: 112025

5 hospitals in Jinan for anti-NMDA receptor encephalitis126 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology
Papers it led8
  1. Elevated Prolactin Levels Are Associated With Increased Severity and Psychiatric Symptoms in Anti-N-Methyl-D-Aspartate Receptor Encephalitis.2025Brain and behavior
  2. Inhibition of NLRP3 inflammasome alleviates cognitive deficits in a mouse model of anti-NMDAR encephalitis induced by active immunization.2024International immunopharmacology
  3. Rapamycin alleviates mitochondrial dysfunction in anti-NMDAR encephalitis mice.2024International immunopharmacology
  4. Efficacy and Safety of Rituximab Treatment for Anti-N-Methyl-d-Aspartate Receptor Encephalitis Without Tumor in Children.2024Pediatric neurology
  5. Elevated cerebrospinal fluid YKL-40 levels in patients with anti-gamma-aminobutyric- acid-B receptor encephalitis.2023Journal of neuroimmunology
  6. Coexistence of NMDAR, GAD65, and SOX1 antibody-associated autoimmune encephalitis.2022Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  7. Recurrent anti-AMPA receptor encephalitis associated with thymus cancer.2021Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  8. Long-term follow-up of a child with anti-AMPA receptor encephalitis.2021Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
Earlier papers (2016–2020)2
  1. Clinical and EEG characteristics analysis of autoimmune encephalitis in children with positive and negative anti-N-methyl- D-aspartate receptor antibodies.2020Annals of palliative medicine
  2. Anti-N-methyl-D-aspartate receptor encephalitis: A case report.2018Medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

Hepatic echinococcosis

肝包虫病

Led 1 of the 152 English-language PubMed papers on hepatic echinococcosis with an author in mainland China, 2021–2025: 0.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

1 hospital in Jinan for hepatic echinococcosis49 hospitals in China for hepatic echinococcosis

No open trial on hepatic echinococcosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 4 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.4%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 1120242025: 112025

9 hospitals in Jinan for idiopathic pulmonary fibrosis333 hospitals in China for idiopathic pulmonary fibrosis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    Phase
    Phase 3
    Started
    2026-09
    Registry
    NCT07687459

    Age 40 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Hohhot, Jinan, Kunming, Nanchang, Nanjing, Nanning, Nanyang, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yichang, Yuncheng, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Papers it led4
  1. Transcription factor MEOX1 accelerates pulmonary fibrosis by regulating mitophagy and senescence.2025European journal of pharmacology
  2. circGRHPR inhibits aberrant epithelial-mesenchymal transformation progression of lung epithelial cells associated with idiopathic pulmonary fibrosis.2024Cell biology and toxicology
  3. The role of autophagy in idiopathic pulmonary fibrosis: from mechanisms to therapies.2022Therapeutic advances in respiratory disease
  4. Secondary organizing pneumonia following occupational acute nitrogen oxide poisoning: a case report.2021The Journal of international medical research
Earlier papers (2016–2020)1
  1. Weighted Gene Coexpression Network Analysis Identifies Key Genes and Pathways Associated with Idiopathic Pulmonary Fibrosis.2019Medical science monitor : international medical journal of experimental and clinical research
All its trials on ClinicalTrials.gov, any status4
  1. Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)RecruitingNCT07687459Study sitePhase 3Start 2026-09
  2. Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary FibrosisTerminatedNCT06097260Study sitePhase 2Start 2023-11
  3. Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT05938920Study sitePhase 2Start 2023-06
  4. A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary FibrosisTerminatedNCT04552899Study sitePhase 3Start 2021-03

Run the PubMed searchClinicalTrials.gov

Other diseases

Lymphangioleiomyomatosis

肺淋巴管平滑肌瘤病

Led 1 of the 45 English-language PubMed papers on lymphangioleiomyomatosis with an author in mainland China, 2021–2025: 2.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

2 hospitals in Jinan for lymphangioleiomyomatosis28 hospitals in China for lymphangioleiomyomatosis

No open trial on lymphangioleiomyomatosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine
Papers it led1
  1. Multisystem Lymphangioleiomyomatosis.2024Radiology

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 13 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 1.7%.

Papers led
13
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 3320222023: 1120232024: 4420242025: 442025

8 hospitals in Jinan for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology
Papers it led13
  1. Connectivity-based striatal subregion microstructural changes in sporadic amyotrophic lateral sclerosis patients: Relation to motor disability, cognitive deficits, and serum biomarkers.2025European journal of neurology
  2. Proximity extension assay reveals serum inflammatory biomarkers in two amyotrophic lateral sclerosis cohorts.2025Neurobiology of disease
  3. CSF Aβ, Tau, Axonal, Synaptic, Glial, Neural, and Inflammatory Biomarkers in Patients With Sporadic Amyotrophic Lateral Sclerosis.2025Neurology
  4. Generation of an induced pluripotent stem cell (iPSC) line (INNDSUi009-A) from a patient with amyotrophic lateral sclerosis due to SOD1 mutation.2025Stem cell research
  5. Glymphatic dysfunction in patients with early-stage amyotrophic lateral sclerosis.2024Brain : a journal of neurology
  6. Abnormal brain functional network dynamics in amyotrophic lateral sclerosis patients with depression.2024Brain imaging and behavior
  7. Elevated peripheral inflammation is associated with choroid plexus enlargement in independent sporadic amyotrophic lateral sclerosis cohorts.2024Fluids and barriers of the CNS
  8. Choroid plexus enlargement in amyotrophic lateral sclerosis patients and its correlation with clinical disability and blood-CSF barrier permeability.2024Fluids and barriers of the CNS
  9. Hypoxia-Induced FUS-circTBC1D14 Stress Granules Promote Autophagy in TNBC.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)
  10. Amygdala abnormalities across disease stages in patients with sporadic amyotrophic lateral sclerosis.2022Human brain mapping
  11. Clinical and Electrophysiological Features of Chronic Motor Axonal Neuropathy.2022Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society
  12. Hypothalamic subregion abnormalities are related to body mass index in patients with sporadic amyotrophic lateral sclerosis.2022Journal of neurology
  13. Hippocampal subfield and anterior-posterior segment volumes in patients with sporadic amyotrophic lateral sclerosis.2021NeuroImage. Clinical
Earlier papers (2016–2020)2
  1. CMAP decrement by low-frequency repetitive nerve stimulation in different hand muscles of ALS patients.2019Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  2. Analysis of clinical and electrophysiological characteristics of 150 patients with amyotrophic lateral sclerosis in China.2019Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

Run the PubMed searchClinicalTrials.gov

Other diseases

Spinal muscular atrophy

脊髓性肌萎缩症

Led no English-language PubMed papers on spinal muscular atrophy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Jinan for spinal muscular atrophy51 hospitals in China for spinal muscular atrophy

No open trial on spinal muscular atrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. Adult Spinal Muscular Atrophy (SMA) China RegistryActive, not recruitingNCT05618379Study siteStart 2023-01

Run the PubMed searchClinicalTrials.gov

Other diseases

Fabry disease

法布雷病

Led 1 of the 73 English-language PubMed papers on Fabry disease with an author in mainland China, 2021–2025: 1.4%.

Papers led
1
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

3 hospitals in Jinan for Fabry disease85 hospitals in China for Fabry disease

No open trial on Fabry disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Pompe disease

庞贝病

Led 2 of the 30 English-language PubMed papers on Pompe disease with an author in mainland China, 2021–2025: 6.7%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

2 hospitals in Jinan for Pompe disease30 hospitals in China for Pompe disease

No open trial on Pompe disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led 1 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

4 hospitals in Jinan for Duchenne muscular dystrophy116 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 1 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

2 hospitals in Jinan for Behçet disease149 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Other diseases

Alport syndrome

Alport 综合征

Led 1 of the 58 English-language PubMed papers on Alport syndrome with an author in mainland China, 2021–2025: 1.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

2 hospitals in Jinan for Alport syndrome60 hospitals in China for Alport syndrome

No open trial on Alport syndrome lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 2 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.3%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

12 hospitals in Jinan for IgA nephropathy346 hospitals in China for IgA nephropathy

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
    Phase
    Phase 3
    Started
    2025-07
    Registry
    NCT06963827

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBaotou, Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanjing, Nantong, Ningbo, Shanghai, Shenzhen, Wuxi, Xiamen, Zhuhai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNephrology
Papers it led2
  1. Immune cells mediate the effect of plasma lipidomes on IgA nephropathy: a Mendelian randomization study.2025Renal failure
  2. The association of normal-range serum phosphorus with immunoglobulin A nephropathy progression: a retrospective cohort study.2024International urology and nephrology
Earlier papers (2016–2020)1
  1. The protective effect and mechanism of rapamycin in the rat model of IgA nephropathy.2019Renal failure
All its trials on ClinicalTrials.gov, any status6
  1. A Study of Mezagitamab in Adults With Kidney Condition Called IgA NephropathyRecruitingNCT06963827Study sitePhase 3Start 2025-07
  2. A Study of Telitacicept for IgA Nephropathy (TELIGAN)Active, not recruitingNCT05799287Study sitePhase 3Start 2023-04
  3. TESTING -ON Post-Trial ObservatioNal Cohort StudyCompletedNCT05434325Study siteStart 2022-12
  4. Atrasentan in Patients With IgA NephropathyActive, not recruitingNCT04573478Study sitePhase 3Start 2020-12
  5. Efficacy and Safety of Abelmoschus Manihot for IgA NephropathyStatus unknownNCT02231125Study sitePhase 4Start 2014-09
  6. Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study)CompletedNCT01560052Study siteN/AStart 2012-05

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led no English-language PubMed papers on primary biliary cholangitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

7 hospitals in Jinan for primary biliary cholangitis173 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Idiopathic inflammatory myopathies with anti-mitochondrial antibodies: Clinical features and treatment outcomes in a Chinese cohort.2019Neuromuscular disorders : NMD
All its trials on ClinicalTrials.gov, any status1
  1. CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)Active, not recruitingNCT05896124Study sitePhase 2Start 2023-08

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led 1 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 1.0%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

2 hospitals in Jinan for primary sclerosing cholangitis90 hospitals in China for primary sclerosing cholangitis

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
    Phase
    Phase 3
    Started
    2026-05
    Registry
    NCT07387549

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesBeijing, Changchun, Guangzhou, Jinan, Nanchang, Shanghai, Tianjin, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Other diseases

Congenital diaphragmatic hernia

先天性膈疝

Led 1 of the 60 English-language PubMed papers on congenital diaphragmatic hernia with an author in mainland China, 2021–2025: 1.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

2 hospitals in Jinan for congenital diaphragmatic hernia46 hospitals in China for congenital diaphragmatic hernia

No open trial on congenital diaphragmatic hernia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Hirschsprung disease

先天性巨结肠

Led 3 of the 161 English-language PubMed papers on Hirschsprung disease with an author in mainland China, 2021–2025: 1.9%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 222025

5 hospitals in Jinan for Hirschsprung disease82 hospitals in China for Hirschsprung disease

No open trial on Hirschsprung disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

Hereditary angioedema

遗传性血管性水肿

Led 1 of the 32 English-language PubMed papers on hereditary angioedema with an author in mainland China, 2021–2025: 3.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

2 hospitals in Jinan for hereditary angioedema30 hospitals in China for hereditary angioedema

No open trial on hereditary angioedema lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Other diseases

Familial adenomatous polyposis

家族性腺瘤性息肉病

Led 1 of the 59 English-language PubMed papers on familial adenomatous polyposis with an author in mainland China, 2021–2025: 1.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

2 hospitals in Jinan for familial adenomatous polyposis76 hospitals in China for familial adenomatous polyposis

No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiation oncology

Run the PubMed searchClinicalTrials.gov

Other diseases

Leber hereditary optic neuropathy

Leber 遗传性视神经病变

Led 3 of the 52 English-language PubMed papers on Leber hereditary optic neuropathy with an author in mainland China, 2021–2025: 5.8%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 0020232024: 0020242025: 002025

1 hospital in Jinan for Leber hereditary optic neuropathy32 hospitals in China for Leber hereditary optic neuropathy

No open trial on Leber hereditary optic neuropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology
Papers it led3
  1. Leber's hereditary optic neuropathy plus dystonia caused by the mitochondrial ND1 gene m.4160 T > C mutation.2022Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
  2. Teaching NeuroImage: Leber Hereditary Optic Neuropathy With Longitudinal Spinal Cord Lesion Mimicking Spinal Cord Infarction.2022Neurology
  3. Leber hereditary optic neuropathy and dystonia overlapping mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes due to m.14459G>A mutation.2021Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

山东大学齐鲁医院

Qilu Hospital of Shandong University

济南

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look at the hospital's own pages linked above.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
Qilu Hospital; Qilu Hospital (Qingdao); Qilu Hospital of Shandong University (Qingdao); Shandong University Qilu Hospital; Qilu Hospital Affiliated to Shandong University; Second Qilu Hospital of Shandong University; Qilu Hospital of Shan Dong University; Qilu hospital of Shandong University

Suggest a correctionDownload the data